Modern strategies for hairy cell leukemia

Journal of Clinical Oncology

Volumn 29, Issue 5, 2011, Pages 583-590

  Grever, Michael R ^a   Lozanski, Gerard ^a  

^a THE OHIO STATE UNIVERSITY WEXNER MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CLADRIBINE; FLUDARABINE; INTERFERON; PENTOSTATIN; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; RITUXIMAB;

BONE MARROW; BONE MARROW DEPRESSION; CANCER CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER REGRESSION; CANCER SURVIVAL; CANCER THERAPY; CELL POPULATION; CLINICAL RESEARCH; DISEASE COURSE; DISEASE FREE SURVIVAL; FEBRILE NEUTROPENIA; FOLLOW UP; HAIRY CELL LEUKEMIA; HUMAN; KIDNEY FUNCTION; LEUKEMIA CELL; LYMPHATIC LEUKEMIA; MICROENVIRONMENT; MINIMAL RESIDUAL DISEASE; PRIORITY JOURNAL; REVIEW; TREATMENT INDICATION; TREATMENT PLANNING; TREATMENT RESPONSE;

HUMANS; KIDNEY; LEUKEMIA, HAIRY CELL; NEOPLASM, RESIDUAL; RECURRENCE;

EID: 79952091306     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2010.31.7016     Document Type: Review

References (75)

1. Bouroncle BA, Wiseman BK, Doan CA: Leukemic reticuloendotheliosis. Blood 13:609-630, 1958
2. Quesada JR, Reuben J, Manning JT, et al: Alpha interferon for induction of remission in hairy-cell leukemia. N Engl J Med 310:15-18, 1984 (Pubitemid 14212475)
3. Grever M, Kopecky K, Foucar MK, et al: Randomized comparison of pentostatin versus interferon alfa-2a in previously untreated patients with hairy cell leukemia: An intergroup study. J Clin Oncol 13:974-982, 1995
4. Golomb HM: Hairy cell leukemia: Treatment successes in the past 25 years. J Clin Oncol 26: 2607-2609, 2008
5. Spiers AS, Parekh SJ, Bishop MB: Hairy-cell leukemia: Induction of complete remission with pentostatin (2′-deoxycoformycin). J Clin Oncol 2:1336-1342, 1984 (Pubitemid 15179534)
6. Kraut EH, Bouroncle BA, Grever MR: Low-dose deoxycoformycin in the treatment of hairy cell leukemia. Blood 68:1119-1122, 1986 (Pubitemid 17186390)
7. Kraut EH, Bouroncle BA, Grever MR: Pentostatin in the treatment of advanced hairy cell leukemia. J Clin Oncol 7:168-172, 1989 (Pubitemid 19048448)
8. Else M, Dearden CE, Matutes E, et al: Longterm follow-up of 233 patients with hairy cell leukaemia, treated initially with pentostatin or cladribine, at a median of 16 years from diagnosis. Br J Haematol 145:733-740, 2009
9. Ho AD, Thaler J, Mandelli F, et al: Response to pentostatin in hairy-cell leukemia refractory to interferon-alpha: The European Organization for Research and Treatment of Cancer Leukemia Cooperative Group. J Clin Oncol 7:1533-1538, 1989
10. Johnston JB, Eisenhauer E, Corbett WE, et al: Efficacy of 2′-deoxycoformycin in hairy-cell leukemia: A study of the National Cancer Institute of Canada Clinical Trials Group. J Natl Cancer Inst 80:765-769, 1988
11. Maloisel F, Benboubker L, Gardembas M, et al: Long-term outcome with pentostatin treatment in hairy cell leukemia patients: A French retrospective study of 238 patients. Leukemia 17:45-51, 2003 (Pubitemid 36175887)
12. Grem JL, King SA, Cheson BD, et al: Pentostatin in hairy cell leukemia: Treatment by the special exception mechanism. J Natl Cancer Inst 81:448-453, 1989 (Pubitemid 19075069)
13. Piro LD, Carrera CJ, Carson DA, et al: Lasting remissions in hairy-cell leukemia induced by a single infusion of 2-chlorodeoxyadenosine. N Engl J Med 322:1117-1121, 1990 (Pubitemid 20149529)
14. Goodman GR, Burian C, Koziol JA, et al: Extended follow-up of patients with hairy cell leukemia after treatment with cladribine. J Clin Oncol 21:891-896, 2003 (Pubitemid 46606450)
15. Chadha P, Rademaker AW, Mendiratta P, et al: Treatment of hairy cell leukemia with 2-chlorodeoxyadenosine (2-CdA): Long-term follow-up of the Northwestern University experience. Blood 106: 241-246, 2005 (Pubitemid 40967199)
16. Huynh E, Sigal D, Saven A: Cladribine in the treatment of hairy cell leukemia: Initial and subsequent results. Leuk Lymphoma 50:12-17, 2009 (suppl 1)
17. Juliusson G, Heldal D, Hippe E, et al: Subcutaneous injections of 2-chlorodeoxyadenosine for symptomatic hairy cell leukemia. J Clin Oncol 13: 989-995, 1995
18. Zenhäusern R, Schmitz SF, Solenthaler M, et al: Randomized trial of daily versus weekly administration of 2-chlorodeoxyadenosine in patients with hairy cell leukemia: A multicenter phase III trial (SAKK 32/98). Leuk Lymphoma 50:1501-1511, 2009
19. Grever MR: How I treat hairy cell leukemia. Blood 115:21-28, 2010
20. Robak T, Jamroziak K, Gora-Tybor J, et al: Cladribine in a weekly versus daily schedule for untreated active hairy cell leukemia: Final report from the Polish Adult Leukemia Group (PALG) of a prospective, randomized, multicenter trial. Blood 109:3672-3675, 2007 (Pubitemid 46641714)
21. Lauria F, Bocchia M, Marotta G, et al: Weekly administration of 2-chlorodeoxyadenosine in patients with hairy-cell leukemia is effective and reduces infectious complications. Haematologica 84: 22-25, 1999 (Pubitemid 29479379)
22. Zinzani PL, Tani M, Marchi E, et al: Long-term follow-up of front-line treatment of hairy cell leukemia with 2-chlorodeoxyadenosine. Haematologica 89:309-313, 2004 (Pubitemid 38788415)
23. Grever MR, Zinzani PL: Long-term follow-up studies in hairy cell leukemia. Leuk Lymphoma 50:23-26, 2009 (suppl 1)
24. Flinn IW, Kopecky KJ, Foucar MK, et al: Long-term follow-up of remission duration, mortality, and second malignancies in hairy cell leukemia patients treated with pentostatin. Blood 96:2981-2986, 2000
25. Hoffman MA: Clinical presentations and complications of hairy cell leukemia. Hematol Oncol Clin North Am 20:1065-1073, 2006
26. Damaj G, Kuhnowski F, Marolleau JP, et al: Risk factors for severe infection in patients with hairy cell leukemia: A long-term study of 73 patients. Eur J Haematol 83:246-250, 2009
27. Matutes E: Immunophenotyping and differential diagnosis of hairy cell leukemia. Hematol Oncol Clin North Am 20:1051-1063, 2006
28. Robak T: Hairy-cell leukemia variant: Recent view on diagnosis, biology and treatment. Cancer Treat Rev 37:3-10, 2011
29. Swerdlow SH, Campo E, Harris NL, et al: WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. Lyon, France, International Agency for Research on Cancer, 2008
30. Sharpe RW, Bethel KJ: Hairy cell leukemia: Diagnostic pathology. Hematol Oncol Clin North Am 20:1023-1049, 2006 (Pubitemid 44380351)
31. Ng JP, Nolan B, Chan-Lam D, et al: Successful treatment of aplastic variant of hairy-cell leukaemia with deoxycoformycin. Hematology 7:259-262, 2002 (Pubitemid 35386066)
32. Gillis S, Amir G, Bennett M, et al: Unexpectedly high incidence of hypoplastic/aplastic foci in bone marrow biopsies of hairy cell leukemia patients in remission following 2-chlorodeoxyadenosine therapy. Eur J Haematol 66:7-10, 2001 (Pubitemid 32099403)
33. Cheson BD, Sorensen JM, Vena DA, et al: Treatment of hairy cell leukemia with 2-chlorodeoxyadenosine via the Group C protocol mechanism of the National Cancer Institute: A report of 979 patients. J Clin Oncol 16:3007-3015, 1998 (Pubitemid 28417420)
34. Hisada M, Chen BE, Jaffe ES, et al: Second cancer incidence and cause-specific mortality among 3104 patients with hairy cell leukemia: A population-based study. J Natl Cancer Inst 99:215-222, 2007
35. Hoffman MA, Janson D, Rose E, et al: Treatment of hairy-cell leukemia with cladribine: Response, toxicity, and long-term follow-up. J Clin Oncol 15:1138-1142, 1997 (Pubitemid 27106300)
36. Kraut EH: Clinical manifestations and infectious complications of hairy-cell leukaemia. Best Pract Res Clin Haematol 16:33-40, 2003
37. Tallman MS, Hakimian D, Variakojis D, et al: A single cycle of 2-chlorodeoxyadenosine results in complete remission in the majority of patients with hairy cell leukemia. Blood 80:2203-2209, 1992
38. Jehn U, Bartl R, Dietzfelbinger H, et al: An update: 12-year follow-up of patients with hairy cell leukemia following treatment with 2- chlorodeoxyadenosine. Leukemia 18:1476-1481, 2004 (Pubitemid 39264069)
39. Habermann TM, Andersen JW, Cassileth PA, et al: Sequential administration of recombinant interferon alpha and deoxycoformycin in the treatment of hairy cell leukaemia. Br J Haematol 80:466-471, 1992
40. Estey EH, Kurzrock R, Kantarjian HM, et al: Treatment of hairy cell leukemia with 2-chlorodeoxyadenosine (2-CdA). Blood 79:882-887, 1992
41. Juliusson G, Liliemark J: Rapid recovery from cytopenia in hairy cell leukemia after treatment with 2-chloro-2′-deoxyadenosine (CdA): Relation to opportunistic infections. Blood 79:888-894, 1992
42. Saven A, Burian C, Adusumalli J, et al: Filgrastim for cladribine-induced neutropenic fever in patients with hairy cell leukemia. Blood 93:2471-2477, 1999 (Pubitemid 29181177)
43. Andrey J, Saven A: Therapeutic advances in the treatment of hairy cell leukemia. Leuk Res 25:361-368, 2001 (Pubitemid 32294280)
44. Thomas DA, Ravandi F, Keating M, et al: Importance of minimal residual disease in hairy cell leukemia: Monoclonal antibodies as a therapeutic strategy. Leuk Lymphoma 50:27-31, 2009 (suppl 1)
45. Hakimian D, Tallman MS, Kiley C, et al: Detection of minimal residual disease by immunostaining of bone marrow biopsies after 2-chlorodeoxyadenosine for hairy cell leukemia. Blood 82:1798-1802, 1993 (Pubitemid 23278770)
46. Tallman MS, Hakimian D, Kopecky KJ, et al: Minimal residual disease in patients with hairy cell leukemia in complete remission treated with 2-chlorodeoxyadenosine or 2-deoxycoformycin and prediction of early relapse. Clin Cancer Res 5:1665-1670, 1999 (Pubitemid 29334443)
47. Wheaton S, Tallman MS, Hakimian D, et al: Minimal residual disease may predict bone marrow relapse in patients with hairy cell leukemia treated with 2-chlorodeoxyadenosine. Blood 87:1556-1560, 1996 (Pubitemid 26056921)
48. Ravandi F, Jorgensen JL, O'Brien SM, et al: Eradication of minimal residual disease in hairy cell leukemia. Blood 107:4658-4662, 2006 (Pubitemid 43882611)
49. Sigal DS, Sharpe R, Burian C, et al: Very long-term eradication of minimal residual disease in patients with hairy cell leukemia after a single course of cladribine. Blood 115:1893-1896, 2010
50. Lauria F, Lenoci M, Annino L, et al: Efficacy of anti-CD20 monoclonal antibodies (Mabthera) in patients with progressed hairy cell leukemia. Haematologica 86:1046-1050, 2001 (Pubitemid 33031870)
51. Thomas DA, Ravandi F, Kantarjian H: Monoclonal antibody therapy for hairy cell leukemia. Hematol Oncol Clin North Am 20:1125-1136, 2006 (Pubitemid 44399849)
52. Hoffman M, Auerbach L: Bone marrow remission of hairy cell leukaemia induced by rituximab (anti-CD20 monoclonal antibody) in a patient refractory to cladribine. Br J Haematol 109:900-901, 2000 (Pubitemid 30609779)
53. Nieva J, Bethel K, Saven A: Phase 2 study of rituximab in the treatment of cladribine-failed patients with hairy cell leukemia. Blood 102:810-813, 2003 (Pubitemid 36917768)
54. Hagberg H, Lundholm L: Rituximab, a chimaeric anti-CD20 monoclonal antibody, in the treatment of hairy cell leukaemia. Br J Haematol 115:609-611, 2001 (Pubitemid 34015651)
55. Angelopoulou MK, Pangalis GA, Sachanas S, et al: Outcome and toxicity in relapsed hairy cell leukemia patients treated with rituximab. Leuk Lymphoma 49:1817-1820, 2008
56. Thomas DA, O'Brien S, Bueso-Ramos C, et al: Rituximab in relapsed or refractory hairy cell leukemia. Blood 102:3906-3911, 2003 (Pubitemid 37486969)
57. Cervetti G, Galimberti S, Andreazzoli F, et al: Rituximab as treatment for minimal residual disease in hairy cell leukaemia. Eur J Haematol 73:412-417, 2004 (Pubitemid 39564364)
58. Kreitman RJ, Fitzgerald DJ, Pastan I: Approach to the patient after relapse of hairy cell leukemia. Leuk Lymphoma 50:32-37, 2009 (suppl 1)
59. Else M, Osuji N, Forconi F, et al: The role of rituximab in combination with pentostatin or cladribine for the treatment of recurrent/refractory hairy cell leukemia. Cancer 110:2240-2247, 2007 (Pubitemid 350100746)
60. Buckstein R, Patel H, Chesney A, et al: Multiply relapsing hairy cell leukemia responsive to repeated courses of rituximab: A case report. Hematology 11:267-270, 2006 (Pubitemid 44963704)
61. Byrd JC, Rai K, Peterson BL, et al: Addition of rituximab to fludarabine may prolong progression-free survival and overall survival in patients with previously untreated chronic lymphocytic leukemia: An updated retrospective comparative analysis of CALGB 9712 and CALGB 9011. Blood 105:49-53, 2005 (Pubitemid 40053062)
62. Byrd JC, Peterson BL, Morrison VA, et al: Randomized phase 2 study of fludarabine with concurrent versus sequential treatment with rituximab in symptomatic, untreated patients with B-cell chronic lymphocytic leukemia: Results from Cancer and Leukemia Group B 9712 (CALGB 9712). Blood 101:6-14, 2003 (Pubitemid 36025880)
63. Kreitman RJ: Recombinant immunotoxins for the treatment of chemoresistant hematologic malignancies. Curr Pharm Des 15:2652-2664, 2009
64. Kreitman RJ, Stetler-Stevenson M, Margulies I, et al: Phase II trial of recombinant immunotoxin RFB4(dsFv)-PE38 (BL22) in patients with hairy cell leukemia. J Clin Oncol 27:2983-2990, 2009
65. Kreitman RJ, Tallman MS, Coutre S, et al: Phase I dose-escalation study of CAT-8015 (HA22), a CD22-specific targeted immunotoxin, in relapsed or refractory hairy cell leukemia. Blood 114:888, 2009 (abstr)
66. Burger JA, Ghia P, Rosenwald A, et al: The microenvironment in mature B-cell malignancies: A target for new treatment strategies. Blood 114: 3367-3375, 2009
67. Cawley J: The biology of hairy cell leukemia. Leuk Lymphoma 50:8-11, 2009 (suppl 1)
68. Cawley JC: The pathophysiology of the hairy cell. Hematol Oncol Clin North Am 20:1011-1021, 2006
69. Kay NE, Han L, Bone N, et al: Interleukin 4 content in chronic lymphocytic leukaemia (CLL) B cells and blood CD8+ T cells from B-CLL patients: Impact on clonal B-cell apoptosis. Br J Haematol 112:760-767, 2001 (Pubitemid 32222850)
70. Niedermeier M, Hennessy BT, Knight ZA, et al: Isoform-selective phosphoinositide 3′-kinase inhibitors inhibit CXCR4 signaling and overcome stromal cell-mediated drug resistance in chronic lymphocytic leukemia: A novel therapeutic approach. Blood 113:5549-5557, 2009
71. Ghosh AK, Secreto CR, Knox TR, et al: Circulating microvesicles in B-cell chronic lymphocytic leukemia can stimulate marrow stromal cells: Implications for disease progression. Blood 115:1755-1764, 2010
72. Al-Fiar F, Meharchand J, Curtis J, et al: Secondary acute myeloid leukemia 4 years after the diagnosis of hairy cell leukemia: Case report and review of the literature. Leuk Res 23:719-721, 1999 (Pubitemid 29324876)
73. Seshadri P: Secondary acute myeloid leukemia following successful treatment of hairy cell leukemia with cladribine. Leuk Res 24:637, 2000
74. Todd SA, Morris TC, Alexander HD: Myelodysplasia terminating in acute myeloid leukemia in a hairy cell leukemia patient treated with 2-deoxycoformycin. Leuk Lymphoma 43:1343-1344, 2002 (Pubitemid 34537984)
75. Hassan R, Gupta M, Kern W, et al: Acute myeloid leukemia following treatment with cladribine for hairy cell leukemia: A case report and review of the literature. Leuk Lymphoma 45:2149-2152, 2004 (Pubitemid 39232867)